Tyrosine kinase inhibitor clinical approval

Drug Approval News: The FDA has approved JNJ’s Rybrevant® (Amivantamab-vmjw plus Lazertinib) as a first line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer.

Lazertinib is a tyrosine kinase inhibitor targeting EGFR with activating mutations including T790M, Del19 and L858R.

Focus Biomolecules can supply Lazertinib for research applications. Contact us for a rapid quotation.